173 related articles for article (PubMed ID: 23145140)
1. Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer.
Lin J; Yu Y; Shigdar S; Fang DZ; Du JR; Wei MQ; Danks A; Liu K; Duan W
PLoS One; 2012; 7(11):e49277. PubMed ID: 23145140
[TBL] [Abstract][Full Text] [Related]
2. Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model.
Lin J; Shigdar S; Fang DZ; Xiang D; Wei MQ; Danks A; Kong L; Li L; Qiao L; Duan W
PLoS One; 2014; 9(7):e103736. PubMed ID: 25072631
[TBL] [Abstract][Full Text] [Related]
3. Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.
Yao M; Ma X; Zhang X; Shi L; Liu T; Liang X; Zhao H; Li X; Li L; Gao H; Jia B; Wang F
Theranostics; 2019; 9(3):747-760. PubMed ID: 30809306
[TBL] [Abstract][Full Text] [Related]
4. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
Shao K; Hou Q; Duan W; Go ML; Wong KP; Li QT
J Control Release; 2006 Oct; 115(2):150-7. PubMed ID: 16963144
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models.
Li M; Tang Z; Zhang D; Sun H; Liu H; Zhang Y; Zhang Y; Chen X
Biomaterials; 2015 May; 51():161-172. PubMed ID: 25771007
[TBL] [Abstract][Full Text] [Related]
6. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
8. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
9. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-loaded red blood cells reduced cardiac toxicity and preserved anticancer activity.
Lucas A; Lam D; Cabrales P
Drug Deliv; 2019 Dec; 26(1):433-442. PubMed ID: 30929538
[TBL] [Abstract][Full Text] [Related]
11. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
12. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z
Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307
[TBL] [Abstract][Full Text] [Related]
13. Targeted multidrug delivery system to overcome chemoresistance in breast cancer.
Tang Y; Soroush F; Tong Z; Kiani MF; Wang B
Int J Nanomedicine; 2017; 12():671-681. PubMed ID: 28176940
[TBL] [Abstract][Full Text] [Related]
14. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
16. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model.
Pan XQ; Wang H; Lee RJ
Pharm Res; 2003 Mar; 20(3):417-22. PubMed ID: 12669962
[TBL] [Abstract][Full Text] [Related]
18. Nanoscaled poly(L-glutamic acid)/doxorubicin-amphiphile complex as pH-responsive drug delivery system for effective treatment of nonsmall cell lung cancer.
Li M; Song W; Tang Z; Lv S; Lin L; Sun H; Li Q; Yang Y; Hong H; Chen X
ACS Appl Mater Interfaces; 2013 Mar; 5(5):1781-92. PubMed ID: 23410916
[TBL] [Abstract][Full Text] [Related]
19. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer.
Bagheri E; Abnous K; Farzad SA; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2020 Nov; 261():118369. PubMed ID: 32882265
[TBL] [Abstract][Full Text] [Related]
20. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
